Amylin Pharmaceuticals (AMLN) Could Be One To Watch On ImClone Bid

Watch Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) on news that Bristol-Myers Squibb Co. (NYSE: BMY) offered to acquire ImClone (Nasdaq: IMCL) at a hefty premium of $60 per share.

Carl Icahn is a shareholder of AMLN and IMCL, in addition to Biogen Idec Inc. (Nasdaq: BIIB).

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Lionsgate faces activist pressure to sell itself in ‘AI era’ - Semafor
• SEC plans crypto investment regime and tokenized stock exemption - Bloomberg